A regulatory element in the 3′‐untranslated region of CEBPA is associated with myeloid/NK/T‐cell leukemia
- 16 November 2020
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 106 (3) , 327-339
Abstract
Objectives: CCAAT/enhancer‐binding protein α (CEBPA) is an essential transcription factor for myeloid differentiation. Not only mutation of the CEBPA gene, but also promoter methylation, which results in silencing of CEBPA, contributes to the pathogenesis of acute myeloid leukemia (AML). We sought for another differentially methylated region (DMR) that associates with the CEBPA silencing and disease phenotype.Methods: Using databases, we identified a conserved DMR in the CEBPA 3′‐untranslated region (UTR).Results: Methylation‐specific PCR analysis of 231 AML cases showed that hypermethylation of the 3′‐UTR was associated with AML that had a myeloid/NK/T‐cell phenotype and downregulated CEBPA. Most of these cases were of an immature phenotype with CD7/CD56 positivity. These cases were significantly associated with lower hemoglobin levels than the others. Furthermore, we discovered that the CEBPA 3′‐UTR DMR can enhance transcription from the CEBPA native promoter. In vitro experiments identified IKZF1‐binding sites in the 3′‐UTR that are responsible for this increased transcription of CEBPA.Conclusions: These results indicate that the CEBPA 3′‐UTR DMR is a novel regulatory element of CEBPA related to myeloid/NK/T‐cell lineage leukemogenesis. Transcriptional regulation of CEBPA by IKZF1 may provide a clue for understanding the fate determination of myeloid vs. NK/T‐lymphoid progenitors.Keywords
This publication has 48 references indexed in Scilit:
- Frequency and Prognostic Impact of CEBPA Proximal, Distal and Core Promoter Methylation in Normal Karyotype AML: A Study on 623 CasesPLOS ONE, 2013
- Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemiaHaematologica, 2010
- The CEBPA gene is down-regulated in acute promyelocytic leukemia and its upstream promoter, but not the core promoter, is highly methylatedHaematologica, 2010
- CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemiaLeukemia, 2010
- Epigenetic Modification of CCAAT/Enhancer Binding Protein α Expression in Acute Myeloid LeukemiaCancer Research, 2008
- Modeling of C/EBPα Mutant Acute Myeloid Leukemia Reveals a Common Expression Signature of Committed Myeloid Leukemia-Initiating CellsCancer Cell, 2008
- Characterization of CEBPA Mutations in Acute Myeloid Leukemia: Most Patients with CEBPA Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic CellsClinical Cancer Research, 2005
- Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemiaNature Genetics, 2001
- Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein α-deficient miceProceedings of the National Academy of Sciences, 1997
- A 30-kDa alternative translation product of the CCAAT/enhancer binding protein alpha message: transcriptional activator lacking antimitotic activity.Proceedings of the National Academy of Sciences, 1993